Immunochemotherapy May Reduce Need for Radical Surgery in Head and Neck Cancer

Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who showed a tumor response to neoadjuvant immunochemotherapy (ICT) and subsequently underwent less extensive surgery experienced markedly improved disease‑free survival and organ preservation rates, a new study reports. The research, published in *Clinical Cancer Research*, was led by Dr. Kunyu Yang, director of the Union Hospital Cancer Center at Tongji Medical College and Huazhong University of Science and Technology in China, and involved a collaborative team of investigators.

In the multicenter cohort, patients received a combination of immune checkpoint inhibitors and chemotherapy before surgery. Those whose tumors responded to this preoperative regimen were eligible for de‑escalated surgical procedures, such as partial resections or organ‑sparing techniques, rather than the more radical operations traditionally required for advanced disease. The study found that this strategy maintained high rates of disease‑free survival while preserving critical structures like the tongue, larynx, and pharyngeal tissues, thereby potentially reducing functional morbidity.

The findings suggest that integrating neoadjuvant ICT with tailored, less invasive surgery may become a viable standard of care for select patients with advanced HNSCC, offering both oncologic efficacy and improved quality of life. Further prospective trials are needed to confirm these outcomes and refine patient selection criteria.